PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
24273102-2	2014	Our objective was to use a neonatal rat model of bronchopulmonary dysplasia to determine if an highly selective cyclooxygenase-2 inhibitor, 5,5-dimethyl-3-(3-fluorophenyl)4-(4-methylsulfonyl)phenyl-2(5H)-furanone (DFU; 10 microg/g body weight), could prevent inflammatory cell influx and protect against lung injury.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	140-212	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	112-128
22495067-11	2012	The expression of activated caspase-3 in ulcers was increased and enhanced further by indomethacin, DFU, and SC-560, but not by celecoxib and valdecoxib.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	100-103	caspase 3	Rattus norvegicus	28-37
23059845-13	2013	Moreover, the protective effect observed in hCOX-2-transfected cells was suppressed by addition of DFU (COX-2 selective inhibitor), and mimicked by addition of PGE(2) in non-transfected cells.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	99-102	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	44-50
23059845-13	2013	Moreover, the protective effect observed in hCOX-2-transfected cells was suppressed by addition of DFU (COX-2 selective inhibitor), and mimicked by addition of PGE(2) in non-transfected cells.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	99-102	cytochrome c oxidase II, mitochondrial	Mus musculus	45-50
20529813-1	2010	Unusual expression of interleukin-1alpha, -1beta and -6 was previously found in the epiphyseal cartilage of rat fetuses prenatally exposed to various non-steroidal anti-inflammatory drugs (NSAID, i.e., ibuprofen, piroxicam, tolmetin) and selective cyclooxygenase-2 inhibitor (DFU).	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	276-279	interleukin 1 alpha	Rattus norvegicus	22-55
21667279-6	2011	However, inhibition of COX-2 by a selective COX-2 inhibitor (DFU) or ibuprofen significantly attenuated MPP(+)-induced VM cell toxicity and VM dopaminergic cell apoptosis, which was accompanied by a decrease in ROS production in VM dopaminergic neurons.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	61-64	prostaglandin-endoperoxide synthase 2	Homo sapiens	23-28
21667279-6	2011	However, inhibition of COX-2 by a selective COX-2 inhibitor (DFU) or ibuprofen significantly attenuated MPP(+)-induced VM cell toxicity and VM dopaminergic cell apoptosis, which was accompanied by a decrease in ROS production in VM dopaminergic neurons.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	61-64	prostaglandin-endoperoxide synthase 2	Homo sapiens	44-49
21667279-6	2011	However, inhibition of COX-2 by a selective COX-2 inhibitor (DFU) or ibuprofen significantly attenuated MPP(+)-induced VM cell toxicity and VM dopaminergic cell apoptosis, which was accompanied by a decrease in ROS production in VM dopaminergic neurons.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	61-64	M-phase phosphoprotein 6	Homo sapiens	104-107
18759857-5	2009	However, at 10(-4) mol/L, DFU augmented histamine-stimulated aminopyrine uptake by 135% and inhibited PGE(2) synthesis by 39%, indicating an inhibition of COX-1 at this higher concentration.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	26-29	cytochrome c oxidase subunit I	Oryctolagus cuniculus	155-160
18952694-6	2009	Under this inflammatory condition, the COX-2 inhibitors DFU (1 micromol/L), DuP-697 (0.5 micromol/L), and Etoricoxib (1 micromol/L) markedly restored and increased the vascular reactivity to NE.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	56-59	prostaglandin-endoperoxide synthase 2	Homo sapiens	39-44
16002525-7	2005	Blood testosterone concentrations in aged rats fed the COX2 inhibitor DFU, at doses of 5, 10, 15, and 20 mg/kg body weight per day were increased by 15, 23, 56, and 120%, respectively, over the levels in the rats receiving no DFU.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	70-73	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	55-59
18438116-7	2008	The response was attenuated to 31 +/- 7 imp x s(-1) after the selective COX-2 inhibitor 5,5-dimethyl-3-(flurorophenyl)-4-(4-methylsulfonyl) phenyl-2(5H)-furanone (DFU) in ileus segments.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	163-166	prostaglandin-endoperoxide synthase 2	Mus musculus	72-77
18216147-6	2008	The COX-2 inhibitor DFU (40 mg.kg(-1).day(-1)) was orally administered to the experimental rats for an additional week.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	20-23	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	4-9
17126828-1	2007	Nimesulide, celecoxib, and DFU (5, 5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl)phenyl-2(5H)-furanone) are nonsteroidal anti-inflammatory drugs (NSAIDs) with selective cyclo-oxygenase (COX)-2 blocking properties and have potent analgesic and anti-inflammatory activities in oral and parenteral administrations.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	27-30	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	174-197
17072738-2	2006	The present study investigated the effects of supplementation of selective cyclooxygenase-2 inhibitor [5,5-dimethyl-3-(3 flurophenyl)-4-(4 methylsulphonal) phenyl-2 (6H) furanone, DFU] to diets on bone metabolism, bone mineral density (BMD), and histomorphometry in middle-aged male rats.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	180-183	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	75-91
16319781-4	2005	Group 1 received DFU (5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl)phenyl-2(5H)-furanone), a highly selective COX-2 inhibitor, at a dose of 1.1 mg/kg/day.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	17-20	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	118-123
17985314-0	2007	Association of maternal pancreatic function and foetal growth in rats treated with DFU, a selective cyclooxygenase-2 inhibitor.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	83-86	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	100-116
17985314-3	2007	The aim of the study was to evaluate the effects of DFU, a selective COX-2 inhibitor, on exocrine and endocrine pancreatic function and the immunoexpression of both COX isoforms in maternal and foetal rat pancreases.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	52-55	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	69-74
16432508-9	2006	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl)phenyl-2(5H)-furanone (DFU), an experimental selective COX-2 inhibitor, blocked SP-induced PG release.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	76-79	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	108-113
16002525-7	2005	Blood testosterone concentrations in aged rats fed the COX2 inhibitor DFU, at doses of 5, 10, 15, and 20 mg/kg body weight per day were increased by 15, 23, 56, and 120%, respectively, over the levels in the rats receiving no DFU.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	226-229	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	55-59
15458776-11	2004	Significant decrease of protein level in non-pregnant rats treated with high DFU dose, and occasionally observed gastrointestinal changes were the only changes noted in groups exposed to the selective COX-2 inhibitor.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	77-80	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	201-206
15256360-7	2005	A selective COX-2 inhibitor 3-(3-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-5,5-dimethyl-(5)H-furan-2-one (DFU) by itself had no effect on basal cell proliferation but significantly reduced the stimulatory effect of TNF-alpha on RMG-1 cells.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	107-110	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	12-17
15256360-7	2005	A selective COX-2 inhibitor 3-(3-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-5,5-dimethyl-(5)H-furan-2-one (DFU) by itself had no effect on basal cell proliferation but significantly reduced the stimulatory effect of TNF-alpha on RMG-1 cells.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	107-110	tumor necrosis factor	Homo sapiens	216-225
15831902-6	2005	Indomethacin (COX-1/COX-2 inhibitor), SC-560 (COX-1 inhibitor), or DFU (COX-2 inhibitor) enhanced atropine sensitive electrically induced contractions of human longitudinal muscle.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	67-70	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	72-77
15730585-3	2005	METHODS: DFU [5,5-dimethyl-3(3-fluorophenyl)-4(4-methylsulfonyl)phenyl-2(5)H)-furanone] is a third-generation, highly specific COX2 enzyme inhibitor.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	9-12	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	127-131
15730585-3	2005	METHODS: DFU [5,5-dimethyl-3(3-fluorophenyl)-4(4-methylsulfonyl)phenyl-2(5)H)-furanone] is a third-generation, highly specific COX2 enzyme inhibitor.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	14-86	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	127-131
15730585-9	2005	DFU 10 mg/kg attenuated injury-induced COX2 immunoreactivity in the cortex (24 and 72 h) and hippocampus (6 and 72 h).	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	0-3	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	39-43
15585326-2	2005	In the present study, whether DFU, a tetrasubstituted furanone initially identified as a selective inhibitor of cyclooxygenase (COX)-2, interferes with transforming growth factor (TGF)-beta-mediated induction of VEGF was determined.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	30-33	vascular endothelial growth factor A	Homo sapiens	212-216
15254689-0	2004	DFU, a selective COX-2 inhibitor, suppresses MCF-7 xenograft tumor growth in mice.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	0-3	prostaglandin-endoperoxide synthase 2	Mus musculus	17-22
12393942-4	2002	The cyclooxygenase 1 inhibitor SC560 (1 micromol/l) effectively inhibited the normoxic prostaglandin I(2) biosynthesis, while the cyclooxygenase 2 inhibitor DFU (1 micromol/l) did not.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	157-160	prostaglandin G/H synthase 2	Oryctolagus cuniculus	130-146
14757153-1	2004	The aim of this study was to compare the tocolytic effect of a selective cyclooxygenase-2 inhibitor, DFU (5,5-dimethyl-3(3-fluorophenyl)-4-(4-methylsulphonyl)phenyl-2(5H)-furanone), indomethacin and nimesulide on myometrial strips isolated from rats in both lipopolysaccharide-induced preterm labour and term labour.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	101-104	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	73-89
10873679-3	2000	Hemodynamic measurements at 4 weeks showed better cardiac function in the group treated with a selective COX-2 inhibitor (DFU; 5 mg/kg/day) for 2 weeks after induction of MI compared to the vehicle treated group.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	122-125	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	105-110
11703020-6	2001	RESULTS: The novel compound DFU was the most selective COX-2 inhibitor in equine, canine, and feline blood; COX-1/COX-2 ratios were 775, 74, and 69, respectively.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	28-31	cytochrome c oxidase subunit II	Equus caballus	55-60
11703020-6	2001	RESULTS: The novel compound DFU was the most selective COX-2 inhibitor in equine, canine, and feline blood; COX-1/COX-2 ratios were 775, 74, and 69, respectively.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	28-31	cytochrome c oxidase subunit I	Canis lupus familiaris	108-113
11703020-6	2001	RESULTS: The novel compound DFU was the most selective COX-2 inhibitor in equine, canine, and feline blood; COX-1/COX-2 ratios were 775, 74, and 69, respectively.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	28-31	cytochrome c oxidase subunit II	Canis lupus familiaris	114-119
11356914-7	2001	The COX-2 inhibitors NS-398 and DFU, but not the COX-1 inhibitor SC-560 or dexamethasone, dose-dependently inhibited CT-induced fluid secretion and PGE(2) release.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	32-35	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	4-9
11302928-1	2001	The metabolic profile of DFU [5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl)phenyl-2(5H)-furanone], a potent and selective COX-2 inhibitor, was characterized using in vitro microsomal and hepatocyte incubations.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	25-28	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	130-135
10642327-7	2000	Likewise, the cyclooxygenase-2 inhibitor 5, 5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone reduced the increases in ARNA and PGE(2) by 43+/-5% and 47+/-8%, respectively.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	41-115	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	14-30
34815495-10	2021	Total hip and femoral neck BMD decreased bilaterally 12 weeks after hospitalisation for DFU.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	88-91	hedgehog interacting protein	Homo sapiens	6-9
9200563-1	1997	The anti-pyretic effect of a selective cyclooxygenase-2 inhibitor, DFU (5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furano ne), was examined in conscious, un-restrained squirrel monkeys (Saimiri sciureus) using a radio telemetric system.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	72-146	prostaglandin-endoperoxide synthase 2	Homo sapiens	39-55
9200563-7	1997	Since the plasma levels achieved for DFU at the dose employed in the present study are below the threshold required for inhibition of cyclooxygenase-1, it is concluded that the anti-pyretic effect of DFU can be attributed predominantly to an inhibitory action on cyclooxygenase-2.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	200-203	prostaglandin-endoperoxide synthase 1	Homo sapiens	134-150
9200563-7	1997	Since the plasma levels achieved for DFU at the dose employed in the present study are below the threshold required for inhibition of cyclooxygenase-1, it is concluded that the anti-pyretic effect of DFU can be attributed predominantly to an inhibitory action on cyclooxygenase-2.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	200-203	prostaglandin-endoperoxide synthase 2	Homo sapiens	263-279
9146894-2	1997	DFU (5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl)phenyl-2(5H)-furan one) was identified as a novel orally active and highly selective cyclo-oxygenase-2 (COX-2) inhibitor.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	0-3	prostaglandin-endoperoxide synthase 2	Homo sapiens	143-160
9146894-2	1997	DFU (5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl)phenyl-2(5H)-furan one) was identified as a novel orally active and highly selective cyclo-oxygenase-2 (COX-2) inhibitor.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	0-3	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	162-167
9083063-5	1997	DuP697, NS-398, DFU, and SC-58125 are selective PGHS-2 inhibitors that act as time-dependent inhibitors of PGHS-2 and rapidly reversible competitive inhibitors of PGHS-1.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	16-19	prostaglandin-endoperoxide synthase 2	Homo sapiens	48-54
9083063-5	1997	DuP697, NS-398, DFU, and SC-58125 are selective PGHS-2 inhibitors that act as time-dependent inhibitors of PGHS-2 and rapidly reversible competitive inhibitors of PGHS-1.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	16-19	prostaglandin-endoperoxide synthase 2	Homo sapiens	107-113
9083063-5	1997	DuP697, NS-398, DFU, and SC-58125 are selective PGHS-2 inhibitors that act as time-dependent inhibitors of PGHS-2 and rapidly reversible competitive inhibitors of PGHS-1.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	16-19	prostaglandin-endoperoxide synthase 1	Homo sapiens	163-169
26244281-8	2015	Furthermore, the addition of DFU (25mg/kg), a selective inhibitor of inflammatory mediator cyclooxygenase-2 (COX-2), potentiated these effects.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	29-32	prostaglandin-endoperoxide synthase 2	Mus musculus	91-107
26244281-8	2015	Furthermore, the addition of DFU (25mg/kg), a selective inhibitor of inflammatory mediator cyclooxygenase-2 (COX-2), potentiated these effects.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	29-32	prostaglandin-endoperoxide synthase 2	Mus musculus	109-114
33160752-7	2021	RESULTS: NRF2 expression was significantly decreased among the T2DM and DFU subjects when compared to the NGT subjects.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	72-75	NFE2 like bZIP transcription factor 2	Homo sapiens	9-13
35504012-10	2022	DFU caused significant decreases in VA and increases in IRF and SRF on OCT that did not recover following injections resumption despite normalization of CFT.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	0-3	plexin A2	Homo sapiens	71-74
35476639-8	2022	RESULTS: CRP had the greatest area under the curve (AUC) of 0.893 for diagnosing grade 2 DFU.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	89-92	C-reactive protein	Homo sapiens	9-12
35476639-12	2022	CONCLUSION: CRP and PCT are the best markers for diagnosing grade 2 and grade 3 DFU respectively.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	80-83	C-reactive protein	Homo sapiens	12-15
33160752-10	2021	CONCLUSION: NRF2 polymorphism rs182428269 is associated with the pathogenesis of T2DM and DFU.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	90-93	NFE2 like bZIP transcription factor 2	Homo sapiens	12-16
32763913-3	2020	Serum and forearm skin analysis, both at protein expression and transcriptomic level, indicated that increased expression of factors such as IFNgamma, VEGF and sVCAM-1 were associated with DFU healing.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	189-192	interferon gamma	Homo sapiens	141-149
32763913-3	2020	Serum and forearm skin analysis, both at protein expression and transcriptomic level, indicated that increased expression of factors such as IFNgamma, VEGF and sVCAM-1 were associated with DFU healing.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	189-192	vascular endothelial growth factor A	Homo sapiens	151-155
32763913-6	2020	The SLCO2A1 and CYP1A1 genes, which were up-regulated at the forearm of Non-Healers, were mainly expressed by the vascular endothelial cell cluster almost exclusively in DFU indicating a potential important role in wound healing.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	170-173	solute carrier organic anion transporter family member 2A1	Homo sapiens	4-11
32763913-6	2020	The SLCO2A1 and CYP1A1 genes, which were up-regulated at the forearm of Non-Healers, were mainly expressed by the vascular endothelial cell cluster almost exclusively in DFU indicating a potential important role in wound healing.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	170-173	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	16-22
32879654-3	2020	We investigated the genetic association of NRF2 single-nucleotide polymorphism rs35652124 with T2DM and DFU and assessed its functional impact.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	104-107	NFE2 like bZIP transcription factor 2	Homo sapiens	43-47
33194039-5	2020	RESULTS: The results of clinical specimens experiments showed that the DFU group exhibited disordered morphology and increased glucose metabolism, decreased activities of the enzymes CAT and SOD in tissues, and increased MDA and NO contents compared to those in the CON group.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	71-74	catalase	Homo sapiens	183-186
33194039-5	2020	RESULTS: The results of clinical specimens experiments showed that the DFU group exhibited disordered morphology and increased glucose metabolism, decreased activities of the enzymes CAT and SOD in tissues, and increased MDA and NO contents compared to those in the CON group.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	71-74	superoxide dismutase 1	Homo sapiens	191-194
32473205-8	2020	Further, expression of pro-inflammatory markers TNF-alpha and IL-6 increased while, the expression of anti-inflammatory marker IL-10 decreased in infected DFU tissues.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	155-158	interleukin 10	Homo sapiens	127-132
31572456-8	2019	Four lncRNAs (FLJ30679, LINC01193, LINC00692, and LINC00641) were observed to be up-regulated in DFU.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	97-100	long intergenic non-protein coding RNA 1193	Homo sapiens	24-33
31572456-8	2019	Four lncRNAs (FLJ30679, LINC01193, LINC00692, and LINC00641) were observed to be up-regulated in DFU.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	97-100	long intergenic non-protein coding RNA 692	Homo sapiens	35-44
31572456-8	2019	Four lncRNAs (FLJ30679, LINC01193, LINC00692, and LINC00641) were observed to be up-regulated in DFU.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	97-100	long intergenic non-protein coding RNA 641	Homo sapiens	50-59
32402839-1	2020	BACKGROUND: This study will explore the effectiveness and safety of autologous PRP in the treatment of patients with DFU.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	117-120	prion protein	Homo sapiens	79-82